Candidate drug replacements for quinacrine in cutaneous lupus erythematosus

被引：7
作者：
Yan, Daisy [1 ,2 ]
Borucki, Robert [1 ,2 ]
Sontheimer, Richard D. [3 ]
Werth, Victoria P. [1 ,2 ]
机构：
[1] Corporal Michael J Crescenz VA Med Ctr, Dept Dermatol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA
来源：
LUPUS SCIENCE & MEDICINE | 2020年 / 7卷 / 01期
基金：
美国国家卫生研究院;
关键词：
autoimmune diseases; lupus erythematosus; systemic; methotrexate; PIMECROLIMUS 1-PERCENT CREAM; DISCOID SKIN-LESIONS; DOUBLE-BLIND; POLYPODIUM-LEUCOTOMOS; INTRAVENOUS IMMUNOGLOBULIN; MYCOPHENOLATE-MOFETIL; ANTIMALARIAL AGENTS; EFFICACY; HYDROXYCHLOROQUINE; METHOTREXATE;
D O I：
10.1136/lupus-2020-000430
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Cutaneous lupus erythematosus (CLE) is a disfiguring and potentially disabling disease that causes significant morbidity in patients. Antimalarials are an important class of medication used to treat this disease and have been the first-line systemic therapy since the 1950s. Quinacrine, in particular, is used as an adjuvant therapy to other antimalarials for improved control of CLE. Quinacrine is currently unavailable in the USA, which has taken away an important component of the treatment regimen of patients with CLE. This paper reviews the evidence of available local and systemic therapies in order to assist providers in choosing alternative treatments for patients who previously benefited from quinacrine therapy.
引用
收藏
页数：8
相关论文
共 96 条
12345678910